创新药板块的强心剂! 富国银行押注Arcellx(ACLX.US)重塑骨髓瘤治疗格局 预言股价将涨超50%

Core Viewpoint - Wells Fargo initiates coverage on Arcellx (ACLX.US) with an "overweight" rating, highlighting its experimental CAR-T therapy "anito-cel" as a potential future pillar in the management of multiple myeloma, which could significantly reshape treatment paradigms [1][4] Group 1: Investment Potential - Wells Fargo sets a target price of $100 for Arcellx, indicating a potential upside of 53% from the recent closing price, providing a strong boost to the currently retracing global innovative drug sector [1] - Despite a year-to-date decline of over 15% in Arcellx's stock price, which has underperformed the S&P 500 index, the bullish outlook from Wells Fargo is seen as a critical support for the stock [1] Group 2: Product Development and Market Position - Anito-cel is expected to receive formal approval in the second-line treatment category by 2028, potentially earlier, which would significantly enhance sales growth trajectories [2] - The peak sales for anito-cel in the fourth-line (4L) market is projected to be $1.6 billion, with approximately $690 million attributed to Arcellx, and could reach around $3.8 billion after gaining second-line and above approvals, with about $1.5 billion for Arcellx [2] Group 3: Competitive Landscape - Despite strong recent clinical trial data for Johnson & Johnson's Tecvayli and Darzalex in multiple myeloma, approximately 30% of patients show extreme resistance to Darzalex, making them ineligible for the Tec-Dara combination therapy [2] - Anito-cel's differentiated design, utilizing Arcellx's D-Domain technology, aims to achieve higher CAR expression and reduce severe immune toxicity, positioning it favorably against existing therapies [4][5] Group 4: Mechanism and Innovation - Anito-cel is a targeted autologous CAR-T cell therapy aimed at relapsed/refractory multiple myeloma, developed in collaboration with Kite Pharma, a subsidiary of Gilead Sciences [3] - The innovative mechanism of anito-cel involves modifying patient T cells to express a chimeric antigen receptor that recognizes BCMA, with a focus on maintaining efficacy while minimizing severe immune-related side effects [4]